Arjun Goyal

Arjun Goyal, M.D., is a co-founder and managing director of Vida Ventures, LLC, a life sciences investment firm founded in 2017, managing approximately $2 billion in assets under management. In addition to this role, Goyal serves as a venture capital advisor at Harvard Business School, providing guidance on fundraising and business model development to students and faculty. Goyal holds positions on the board of directors for multiple biotechnology companies, including Alterome Therapeutics, Affini-T Therapeutics, Centessa Pharmaceuticals, Quanta Therapeutics, Scorpion Therapeutics, and Pionyr Immunotherapeutics, where significant accomplishments include Pionyr's acquisition by Gilead for around $1.5 billion. Goyal's previous experience includes serving on the board of Kinnate Biopharma and acting as an investor at Asklepios BioPharmaceutical, contributing to its acquisition by Bayer for approximately $4 billion. Arjun Goyal's educational background includes an MBA from Harvard Business School, a Master of Philosophy from the University of Cambridge, and a Bachelor of Medicine and Bachelor of Surgery from the University of Melbourne, among other credentials.